Five Prime Therapeutics Inc. (NASDAQ:FPRX) has received a consensus recommendation of “Buy” from the seven analysts that are currently covering the firm. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $54.00.

A number of research analysts recently weighed in on FPRX shares. Credit Suisse Group AG reiterated a “buy” rating on shares of Five Prime Therapeutics in a report on Tuesday, July 12th. Jefferies Group set a $60.00 target price on Five Prime Therapeutics and gave the company a “buy” rating in a report on Friday, August 5th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $58.00 target price (up previously from $45.00) on shares of Five Prime Therapeutics in a report on Monday, August 8th.

In other news, Director Peder Jensen sold 12,195 shares of Five Prime Therapeutics stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $49.50, for a total transaction of $603,652.50. Following the sale, the director now directly owns 12,195 shares of the company’s stock, valued at $603,652.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William R. Ringo sold 500 shares of Five Prime Therapeutics stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $50.77, for a total value of $25,385.00. Following the sale, the director now directly owns 500 shares in the company, valued at $25,385. The disclosure for this sale can be found here. 5.30% of the stock is owned by company insiders.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/five-prime-therapeutics-inc-nasdaqfprx-given-average-rating-of-buy-by-brokerages.html

Several hedge funds have recently made changes to their positions in the company. Williams Jones & Associates LLC raised its stake in shares of Five Prime Therapeutics by 87.3% in the second quarter. Williams Jones & Associates LLC now owns 11,066 shares of the company’s stock worth $458,000 after buying an additional 5,159 shares during the last quarter. Sterling Capital Management LLC acquired a new stake in shares of Five Prime Therapeutics during the second quarter worth about $546,000. Schwab Charles Investment Management Inc. raised its stake in shares of Five Prime Therapeutics by 215.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 143,992 shares of the company’s stock worth $5,955,000 after buying an additional 98,353 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Five Prime Therapeutics by 5.4% in the second quarter. Legal & General Group Plc now owns 4,077 shares of the company’s stock worth $169,000 after buying an additional 208 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its stake in shares of Five Prime Therapeutics by 10.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 19,875 shares of the company’s stock worth $822,000 after buying an additional 1,908 shares during the last quarter. 86.49% of the stock is currently owned by institutional investors and hedge funds.

Five Prime Therapeutics (NASDAQ:FPRX) traded down 2.15% during midday trading on Wednesday, hitting $50.89. The company had a trading volume of 161,824 shares. The stock has a 50 day moving average of $47.48 and a 200 day moving average of $43.86. Five Prime Therapeutics has a 52-week low of $14.70 and a 52-week high of $55.00. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of 5.72 and a beta of 4.51.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07. Five Prime Therapeutics had a return on equity of 69.59% and a net margin of 63.88%. The firm had revenue of $9.23 million for the quarter, compared to analysts’ expectations of $6.38 million. During the same quarter last year, the firm earned ($0.45) earnings per share. The firm’s revenue for the quarter was up 46.1% compared to the same quarter last year. On average, analysts anticipate that Five Prime Therapeutics will post ($2.37) EPS for the current year.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

5 Day Chart for NASDAQ:FPRX

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.